Health Condition 1: C53- Malignant neoplasm of cervix uteri
Conditions
Interventions
Intervention1: Not applicable: Not applicable
Sponsors
MHRDUAY
Centre of Excellence
Eligibility
Inclusion criteria
Inclusion criteria: 1)Histologically confirmed Cervical Carcinoma 2)Treatment naive 3)Tumour and adjacent normal tissue sample preserved byTMH/ACTREC Tumour Tissue Repository 4)Patient consented for study by TMH/ACTREC Tumour Tissue repository Repository
Exclusion criteria
Exclusion criteria: 1)Patients who have received any form of prior treatment 2)Patients not consented by TMH/ACTREC Tumour Tissue Repository 3)Patients whose clinical history is not available 4)Patients for whom paired normal tissue or blood is not collected
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Using a patient centric and patient specific multi-omics approach to holistically characterize molecular programs involved in development of Cervical Cancer (CA Cervix).Timepoint: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| This study aims to perform a comprehensive multi-omics profiling of cervical cancer patients using whole genome/whole exome, whole transcriptome and whole proteome approaches. This data will constitute a valuable resource to identify novel drivers of cervical cancer that can be probed for therapeutic vulnerabilities using functional genomic screens. These results will thus identify novel mechanisms/pathways responsible for development of cervical cancer. The candidate proteogenomic signatures identified and validated using various techniques will be useful as markers for prognosis, monitoring disease recurrence, predict early onset of the disease occurrence, and may eventually be used to develop diagnostic tests.Timepoint: 3 years | — |
Countries
India
Contacts
Public ContactYogesh Kembhavi
Tata Memorial Centre
Outcome results
None listed